News

Allon releases results of Phase II schizophrenia cognitive impairment clinical trial

VANCOUVER — July 9, 2009 - Allon Therapeutics Inc. (TSX: NPC) today released top-line results from a Phase IIa clinical trial showing that the Company’s lead neuroprotective drug candidate, davunetide intranasal (AL-108), has a positive impact on the ability of schizophrenia patients to carry out... Continue reading →

Allon receives notice of allowance from European Patent Office for lead compound davunetide (NAP) as Alzheimer’s treatment

VANCOUVER — May 28, 2009 - Allon Therapeutics Inc. (TSX:NPC) announced today that the European Patent Office has issued a notice of allowance for a patent covering the composition and method of use of the Company’s lead neuroprotective compound davenutide (NAP) as a treatment for Alzheimer’s dise... Continue reading →

Allon Therapeutics releases First Quarter operating results

VANCOUVER — May 14, 2009 - Allon Therapeutics Inc. (TSX:NPC) reported today in its First Quarter 2009 operating results that the Company is on track to achieve its 2009 milestones, including completing a partnership with a major pharmaceutical company and advancing the clinical development of lea... Continue reading →

Issued U.S. patent strengthens IP for Allon technology platform

VANCOUVER — April 14, 2009 - Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a U.S. patent covering the chemical composition of two componen... Continue reading →

Allon CEO to present at Cowen and Company investment conference

VANCOUVER — March 17, 2009 - Allon Therapeutics Inc., (TSX: NPC) has announced that President and CEO Gordon McCauley has been invited to present the Company’s progress on its 2009 corporate and clinical milestones today at 3:10 p.m. EDT in Boston at the 29th Annual Cowen and Company Health Care ... Continue reading →

← Older posts Newer posts →